NICE
NICE launches new BNF prescribing app
June 15, 2012Medical Communications, Sales and Marketing BNF, NICE, app, digital, pharma
NICE has launched a new app that allows users to search all medicines listed in the British National Formulary. The …
Roche’s Zelboraf rejected by NICE
June 15, 2012Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma
NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …
NICE recommends Xarelto for stroke prevention
May 23, 2012Sales and Marketing Bayer, DVT, NICE, Pradaxa, Xarelto, anticoagulant
NICE is recommending Bayer’s anticoagulant pill Xarelto to help reduce the risk of stroke in certain patients. The watchdog’s final …
NICE to be sidelined on cost effectiveness – once again
May 17, 2012Sales and Marketing NICE, VBP
Health secretary Andrew Lansley has confirmed that NICE will no longer direct the NHS on the cost effectiveness of drugs. …
NICE comes out fighting against appraisal delays story
May 17, 2012Sales and Marketing Daily Mail, Dillon, NHS, NICE, Pfizer, Victrelis
NICE has criticised a report that says the watchdog has taken up to nine years to appraise certain drugs. The …
Price cut sways NICE on Zytiga
May 16, 2012Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer
NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance. In its final guidance, the watchdog is recommending …
Scottish watchdog rejects Yervoy
May 14, 2012Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma
The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy. The SMC said that Yervoy (ipilimumab), which has …
NICE changes its mind on Botox
May 11, 2012Sales and Marketing Allergan, Botox, NHS, NICE
NICE is now recommending Allergan’s Botox for chronic migraines, reversing its previous decision. The watchdog said in final draft guidance …
Discount sways NICE into recommending Tarceva
May 10, 2012Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer
NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease. The watchdog said …
Novartis ponders Lucentis price cut in UK
May 8, 2012Medical Communications, Sales and Marketing Lucentis, NICE, avastin, market access
Novartis could cut the price of its eye drug Lucentis in the UK to head off moves to switch patients …
NICE no to GSK’s lupus drug Benlysta
April 27, 2012Sales and Marketing Andrew Dillon, Benlysta, GSK, Lupus, NICE
NICE is still not recommending GlaxoSmithKline’s lupus drug Benlysta, as it believes the treatment is too costly. In its final …
Two new hep C pills recommended by NICE
April 25, 2012Sales and Marketing Incivo, Janssen, MSD, NICE, Victrelis, hep C
NICE has given its final recommendation for two new hepatitis C pills in an expedited review. Janssen’s Incivo (telaprevir) and …
Abbott launches online tool for ankylosing spondylitis
April 23, 2012Medical Communications AS, Abbott, NHS, NICE, ankylosing spondylitis
Abbott has launched a new online assessment tool that has the potential to change the landscape of ankylosing spondylitis (AS) …
NICE rejects Avastin for breast cancer
April 18, 2012Sales and Marketing EMA, NICE, Roche, avastin, breast cancer
In a blow for Roche, NICE has turned down its cancer drug Avastin because of ‘too many uncertainties’ over cost …
NICE rejects Halaven for breast cancer
April 3, 2012Sales and Marketing Eisai, Halaven, NICE, breast cancer
NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs. In its final …
